ImmuPharma (IMM) News Today GBX 1.57 -0.02 (-1.26%) (As of 12:11 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ImmuPharma plc (25I.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comImmupharma Share Chat (IMM)September 18, 2024 | lse.co.ukImmuPharma obtains second warrant extension with IncantheraSeptember 10, 2024 | lse.co.ukImmuPharma narrows losses in first half as expenses fallSeptember 10, 2024 | lse.co.ukT42 Iot Track. Share ChatAugust 28, 2024 | lse.co.ukGuardian Metal Resources PLC Share Price (GMET)August 7, 2024 | lse.co.uk5x Long Qqq Share ChatMay 29, 2024 | lse.co.ukHsbc Bk.24 Share ChatMay 26, 2024 | lse.co.ukInvestigational Drugs for Chronic Inflammatory Demyelinating PolyneuropathyMay 8, 2024 | msn.comLooking for top FTSE 100 value shares? Here’s one I’d buy without hesitationMay 8, 2024 | msn.comImmupharma jumps amid new IP strategy for P140 technology platformApril 2, 2024 | lse.co.ukIncanthera says first order from skincare deal doublesMarch 25, 2024 | lse.co.ukSMALL CAP MOVERS: Versarien soars as advanced materials group offloads non-core assetsMarch 15, 2024 | msn.comImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developmentsMarch 8, 2024 | finance.yahoo.comImmuPharma PLC IMMFebruary 24, 2024 | morningstar.comUK government borrowing surplus rises in January from prior yearFebruary 21, 2024 | lse.co.ukImmuPharma PLC (25I.SG)January 17, 2024 | ca.finance.yahoo.comEARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrowsDecember 19, 2023 | lse.co.ukImmuPharma launches GBP2 million fund raise as interim loss narrowsAugust 31, 2023 | lse.co.ukImmuPharma to Raise up to GBP1.85 Mln to Fund R&D Pipeline, Working CapitalAugust 31, 2023 | marketwatch.comImmuPharma agrees 12 month extension to Incanthera warrant instrumentAugust 21, 2023 | lse.co.ukImmuPharma "absolutely delighted" to push on with new clinical trialJune 27, 2023 | proactiveinvestors.comImmuPharma presses on with next phase of Lupuzor clinical trialsJune 19, 2023 | proactiveinvestors.comImmuPharma "looking forward with quiet confidence" to FDA responseMay 24, 2023 | proactiveinvestors.comFTSE 100 remains higher but off best with Wall Street indicated mixedMay 18, 2023 | uk.investing.comImmuPharma Shares Rise on Positive Guidance From US FDA for P140May 18, 2023 | marketwatch.comImmuPharma shares jump 6.5% after FDA updateMay 18, 2023 | proactiveinvestors.comImmuPharma says CIDP trial will begin in the second half after meeting with US regulatorMay 18, 2023 | proactiveinvestors.comSystemic Lupus Erythematous SLE Drug Market, Global Outlook and Forecast 2023-2029May 12, 2023 | marketwatch.comImmuPharama eyes clinical trial progressMay 11, 2023 | proactiveinvestors.comImmuPharma eyes clinical trial progressMay 11, 2023 | proactiveinvestors.comImmuPharma "looking forward" to upcoming FDA meetingsApril 27, 2023 | proactiveinvestors.comImmuPharma partner gets FDA meeting dateApril 19, 2023 | proactiveinvestors.comImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical ProgramApril 12, 2023 | marketwatch.comImmuPharma rises 4% after it reveals headway with lead assetApril 12, 2023 | proactiveinvestors.comImmuPharma makes progress developing second indication for lead assetApril 12, 2023 | proactiveinvestors.comSystemic Lupus Erythematosus (SLE) Drugs Market Top Players By 2031March 30, 2023 | marketwatch.comImmuPharma: US partner has submitted Lupuzor phase II/III trial protocolMarch 27, 2023 | proactiveinvestors.comImmuPharma Shares Rise on Lupus Candidate FDA Trial SubmissionMarch 27, 2023 | marketwatch.comImmuPharma: US partner submits Lupuzor phase II/III trial protocolMarch 27, 2023 | proactiveinvestors.comImmuPharma collaborates on potential 'radioactive bullet' to kill cancerMarch 6, 2023 | proactiveinvestors.comCutaneous Lupus Erythematosus (CLE) Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of SolutionsFebruary 14, 2023 | marketwatch.comImmuPharma expects new Lupozor study to begin in H2 2023February 8, 2023 | proactiveinvestors.comImmuPharma agrees study design with Avion for lupus programme LupuzorFebruary 6, 2023 | lse.co.ukImmuPharma Shares Rise After Lupuzor Trial ConfirmedFebruary 6, 2023 | marketwatch.comImmuPharma partner agrees phase II/III clinical trial processFebruary 6, 2023 | proactiveinvestors.comSystemic Lupus Erythematosus (SLE) Drugs Market Size 2023 Report Examines Latest Trends and Key Drivers Supporting Regional Outlook 2028January 10, 2023 | marketwatch.comUK data highlights oncoming recessionDecember 22, 2022 | fxstreet.comImmuPharma Shares Rise After Executives Waive Part of SalaryDecember 22, 2022 | marketwatch.comImmuPharma says it has ‘clear objective’ to advance lupus treatment to next clinical trial in 2023December 22, 2022 | proactiveinvestors.com Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. IMM Media Mentions By Week IMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMM News Sentiment▼0.000.47▲Average Medical News Sentiment IMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMM Articles This Week▼00▲IMM Articles Average Week Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OBI News HEMO News OPTI News ONC News SNG News IXI News FAB News EVG News DEST News VAL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:IMM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
